Scienture Posts 216% Revenue Surge on Arbli™ Launch, Eyes REZENOPY™ Rollout
Event summary
- Scienture reported $431.6M in 2025 revenue, up 216% YoY, driven by Arbli™ launch in Q3 2025.
- Gross margin expanded by 7,240 basis points to 76.8%, transitioning from wholesale to branded pharmaceuticals.
- Company secured GPO agreements for Arbli™ covering 100M lives and REZENOPY™ reaching 60% of U.S. institutional market.
- Cash position improved to $6.7M with $5.2M in positive working capital as of December 31, 2025.
The big picture
Scienture's turnaround reflects the shift from low-margin wholesale operations to higher-margin branded products, positioning it in competitive specialty pharmaceutical markets. The company's focus on unmet needs in hypertension and opioid overdose treatment aligns with broader healthcare trends toward targeted therapies and institutional access expansion.
What we're watching
- Commercial Momentum
- Whether Scienture can sustain Arbli™'s early traction in the $241M losartan market.
- Regulatory Execution
- The pace at which REZENOPY™ gains formulary inclusion following its Q2 2026 launch.
- Strategic Acquisitions
- How potential portfolio expansions will impact Scienture's long-term growth trajectory.
Related topics